Patents by Inventor Douglas Wade Beight

Douglas Wade Beight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AKT inhibitors
    Patent number: 8436002
    Abstract: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: May 7, 2013
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Joshua Ryan Clayton, MariJean Eggen, Kenneth James Henry, Jr., Deidre Michelle Johns, Saravanan Parthasarathy, Huaxing Pei, Mark Edward Rempala, Jason Scott Sawyer
  • AKT INHIBITORS
    Publication number: 20120149684
    Abstract: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.
    Type: Application
    Filed: October 20, 2010
    Publication date: June 14, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Joshua Ryan Clayton, MariJean Eggen, Kenneth James Henry, JR., Deidre Michelle Johns, Saravanan Parthasarathy, Huaxing Pei, Mark Edward Rempala, Jason Scott Sawyer
  • Quinolinyl-pyrrolopyrazoles
    Patent number: 7834029
    Abstract: A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: November 16, 2010
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Jason Scott Sawyer, Jonathan Michael Yingling
  • Compounds as pharmaceutical agents
    Patent number: 7405299
    Abstract: The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: July 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Timothy Paul Burkholder, Todd Vincent Decollo, Alexander Glenn Godfrey, Charles Raymond Heap, Chi-Hsin Richard King, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Yan Wang, Clive Gideon Diefenbacher, Thomas Albert Engler, Sushant Malhotra, Sreenivasa Reedy Mundla
  • Pyrazolopyridine derivatives as pharmaceutical agents
    Patent number: 7365066
    Abstract: Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: April 29, 2008
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Rosanne Bonjouklian, Junkai Liao, William Thomas McMillen, Brandon Lee Parkhurst, Jason Scott Sawyer, Jonathan Michael Yingling, Jeremy Schulenburg York
  • Quinolinyl-pyrrolopyrazoles
    Patent number: 7265225
    Abstract: A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: September 4, 2007
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Jason Scott Sawyer, Jonathan Michael Yingling
  • Aromatic amides
    Patent number: 7129245
    Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: October 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Trelia Joyce Craft, Carl Penman Denny, Jeffry Bernard Franciskovich, Theodore Goodson, Jr., Steven Edward Hall, David Kent Herron, Sajan Joseph, Valentine Joseph Klimkowski, Jeffrey Alan Kyle, John Joseph Masters, David Mendel, Guy Milot, Marta Maria Pi{hacek over (n)}elro-Nú{hacek over (n)}ez, Jason Scott Sawyer, Robert Theodore Shuman, Gerald Floyd Smith, Anne Louise Tebbe, Jennifer Marie Tinsley, Leonard Crayton Weir, James Howard Wikel, Michael Robert Wiley, Ying Kwong Yee
  • Pyrrole derivatives as pharmaceutical agents
    Patent number: 7087626
    Abstract: Novel pyrrazole derivative compounds and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: August 8, 2006
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Todd Vincent DeCollo, Alexander Glenn Godfrey, Theodore Goodson, Jr., Hong-Yu Li, William Thomas McMillen, Shawn Christopher Miller, Jason Scott Sawyer, Edward C. R. Smith, Jonathan Michael Yingling
  • sPLAinhibitors
    Patent number: 6992100
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, John David Jandzinski
  • sPLA2 inhibitors
    Patent number: 6974831
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 13, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • sPLA2 inhibitors
    Patent number: 6930123
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: August 16, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Antithrombotic agents
    Patent number: 6924296
    Abstract: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: August 2, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, John Joseph Masters, Jason Scott Sawyer, Robert Theodore Shuman, Michael Robert Wiley, Ying Kwong Yee
  • Spla2 inhibitors
    Patent number: 6916840
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: July 12, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • sPLA2 inhibitors
    Patent number: 6872743
    Abstract: A novel class of tetracyclic compounds represented by the formula I wherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: March 29, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer
  • Heterocycle substituted diphenyl leukotriene antagonists
    Publication number: 20040198779
    Abstract: The invention relates to novel heterocycle substituted diphenyl leukotriene B4 (LTB4) antagonists, to compositions containing such compounds, and to methods of using such compounds for treatment of inflammatory diseases.
    Type: Application
    Filed: January 28, 2004
    Publication date: October 7, 2004
    Inventors: Jason Scott Sawyer, Douglas Wade Beight, Edward C. R. Smith, William Thomas McMillen
  • Heterocycle substituted diphenyl leukotriene antagonists
    Patent number: 6797723
    Abstract: The invention relates to novel heterocycle substituted diphenyl leukotriene B4 (LTB4) antagonists, to compositions containing such compounds, and to methods of using such compounds for treatment of inflammatory diseases.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: September 28, 2004
    Assignee: Eli Lilly and Company
    Inventors: Jason Scott Sawyer, Douglas Wade Beight, Edward C R Smith, William Thomas McMillen
  • Antithrombotic amides
    Patent number: 6780878
    Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: August 24, 2004
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Trelia Joyce Craft, Jeffry Bernard Franciskovich, Theodore Goodson, Jr., Steven Edward Hall, David Kent Herron, Sajan Joseph, Valentine Joseph Klimkowski, Jeffrey Alan Kyle, John Joseph Masters, David Mendel, Guy Milot, Marta Maria Piñeiro-Núñez, Jason Scott Sawyer, Robert Theodore Shuman, Gerald Floyd Smith, Anne Louise Tebbe, Jennifer Marie Tinsley, Leonard Crayton Weir, James Howard Wikel, Michael Robert Wiley, Ying Kwong Yee
  • Aromatic amides
    Patent number: 6759414
    Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: July 6, 2004
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Trelia Joyce Craft, Carl Penman Denny, Jeffry Bernard Franciskovich, Theodore Goodson, Jr., Steven Edward Hall, David Kent Herron, Sajan Joseph, Valentine Joseph Klimkowski, Jeffrey Alan Kyle, John Joseph Masters, David Mendel, Guy Milet, Marta Maria Piñeiro-Nuñez, Jason Scott Sawyer, Robert Theodore Shuman, Gerald Floyd Smith, Anne Louise Tebbe, Jennifer Marie Tinsley, Leonard Crayton Weir, James Howard Wikel, Michael Robert Wiley, Ying Kwong Yee
  • Novel spla2 inhibitors
    Publication number: 20040092543
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: June 16, 2003
    Publication date: May 13, 2004
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin Jr, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, John David Jandzinski
  • sPLA2 inhibitors
    Patent number: 6730694
    Abstract: A class of novel substituted pyrrole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: January 7, 2003
    Date of Patent: May 4, 2004
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, John Michael Morin, Jr., Jason Scott Sawyer, Edward C R Smith